Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Continental AG announced this week that it has given $5 million to Wildlife Mississippi to finance that organization’s purchase of 1,000 acres along Bayou Pierre west of Hazlehurst in Copiah County. One parcel was purchased from a timber company and one was bought from an individual, said James Cummins, executive director of Wildlife Mississippi The waterway, which empties into the Mississippi River in Claiborne County, is the only home of a fish listed as federally threatened, the bayou darter. Cummins said his group plans to improve habitat by planting native hardwood trees on part of the land which is now planted in pines, and by removing invasive species from areas where there are now hardwoods. The initial restoration work is expected to take place over the winter and spring. Wildlife Mississippi already owns an adjoining 320 acres. “What we’re trying to do is build a larger conservation area around Bayou Pierre,” Cummins said. The stream is plagued by erosion because the channel of the Mississippi is deepening, and Bayou Pierre is carving out a deeper channel of its own to get down to the lower level of the river it feeds into. That’s causing erosion of Bayou Pierre’s banks, harming the stream’s water quality and further stressing the bayou darter. The problem has been going on for years, exacerbated by agriculture and gravel mining in the Bayou Pierre watershed. The U.S. Fish and Wildlife Service has been trying to organize landowners to improve the situation, and Wildlife Mississippi’s entry is one response. Cummins said Wildlife Mississippi was approached by Continental even before the company announced its $1.45 billion tire plant near Clinton in February, and Continental said the transaction was completed in April. “It’s important for Continental to work with local environmental groups to conserve the areas where we’re investing,” Continental Project Manager Grant Bovim said in a statement. Continental ultimately plans 2,500 jobs at the Hinds County site. Wildlife Mississippi will retain the land and is considering public access to the tract in the future. Cummins said the group would like to encourage canoeing and kayaking in Bayou Pierre. ___ Follow Jeff Amy at: http://twitter.com/jeffamy . Read his work at http://bigstory.ap.org/author/jeff-amy .
[A]: Tire company gives $5M to protect land around Bayou Pierre.


[Q]: The shutdown began in late March in the Pacific nation of about 5 million, and a state of national emergency was declared to stifle local transmissions of the respiratory disease. “No one goes home, everyone goes into a managed facility,” Prime Minister Jacinda Ardern said, adding that 14 days spent in a government-approved facility would be a prerequisite for all foreign travellers. “Even one person slipping through the cracks and bringing the virus in can see an explosion in cases, as we have observed with some of our bigger clusters,” she told a media briefing in Wellington on Thursday. Ardern added that her cabinet would decide whether to extend the nationwide curbs on April 20, two days before the lockdown is set to end. The lockdown has reduced domestic transmissions, authorities said, with a steady fall this week in the daily rise in infections. The tally of infections rose by 29 to stand at 1,239 on Thursday, for the lowest daily rise since March 21, a sign the epidemic could be on the retreat since the lockdown began 15 days ago. Overnight, 35 people were declared to have recovered. New Zealand, like neighbouring Australia, has fewer infections than many countries and the pace of infections in both nations has slowed dramatically in the past week. Despite some signs of a plateau in infections, the government said it had no plans to relax the curbs over the Easter weekend and warned of hefty fines for non-essential travel then. Police will step up activity around holiday spots during the Easter holidays, authorities said, with some roadblocks planned. Interactive graphic tracking global spread of coronavirus: open tmsnrt.rs/3aIRuz7 in an external browser.
[A]: New Zealand orders quarantine for returning citizens in coronavirus battle.


[Q]: As the drug is still under development, there was no discussion of costs. This is a humanized monoclonal antibody and the story might have mentioned some of the drugs currently on the market to treat other disorders such as bevacizumab (Avastin) or adalimub (Humira). This could have led to some discussion about costs because these are not inexpensive medications. The story merely mentions that this drug had ‘shown promise’ and that the studies reported are ‘encouraging’ because they indicate that people can tolerate the drug for 2- 4 years without safety concerns. Promise of what? What does the drug do? Although the story mentions amyloid accumulation, it failed to explain that though amyloid accumulation is seen in Alzheimer’s disease, it isn’t clear whether it causes symptoms or is secondary to the disease process. The story would have added valuable context by at least mentioning the results of the placebo-controlled study from which the patients in this extension study were drawn. http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-newsArticle&ID=1166655 That study found that the drug had no effect on symptoms in the study group overall, although specific subgroups seemed to benefit in an after-the-fact analysis that was not part of the original study design. The story indicated that some patients taking the higher does of the drug experienced headache, memory loss, hallucinations, reduced coordination or other symptoms. From the information in the story, it appeared that 8% (21/262) of patients participating in a second study using the lower dose of the medication had some anomalies on MRI scan but no reported symptoms. At the end of this story, it was reported that the results had only been presented at a meeting and therefore considered only as preliminary until they were reviewed. In addition, the story indicated that the study reported on was an open-label trial. But it doesn’t explain what open-label means – hardly a consumer-friendly term. Wanna do a poll on how many readers know what it means? (In an open-label trial, both the clinician and patient know what it is that they are taking; the potential impact of that on results should be obvious.) Nonethless, we’ll give the story the benefit of the doubt, largely on the back of one of the expert sources being quoted:  “it is too early to tell from the data from this small Phase 2 safety trial.” (Although, again, do we expect that most readers know what a Phase 2 trial really means?). The story did not engage in overt disease-mongering. The story included a quote from Dr. Ian Murray who did not appear to have a role in the studies reported on as well as comments from Dr. Salloway, lead author of the study. But we’re going to rule it unsatisfactory because the story should have noted that Dr. Salloway, according to previous disclosures available online, has received research funding and has consulting relationships with numerous drug companies, including Pfizer, which makes bapineuzumab. The story failed to explain how patients taking bapineuzumab compared with those who did not take the drug. Without this information, it is impossible to evaluate the value this medication may have to patients. The story also should have put the findings seen with bapineuzumab in context with those of the other approved drugs (Aricept, etc) that have limited efficacy or perhaps mentioned the other drugs that are in testing. The subject of the story is the drug bapineuzumab, which was reported as not yet available to consumers. It would have been useful to include a link to Clinicaltrials.gov so that readers who might be interested could learn about the other trials being conducted. http://clinicaltrials.gov/ct2/results?term=Bapineuzumab This story did not overstate the novelty of the drug reported on. But the story also could have mentioned that there are several similar drugs undergoing preliminary testing. This story did not rely solely on a news release.
[A]:
Experimental Drug Might Help Fight Alzheimer’s After All